BRPI0408331B8 - conjugado de proteína, processo para preparação do dito conjugado de proteína, composição farmacêutica e processo para prolongar a meia vida útil in vivo de um polipeptídeo fisiologicamente ativo - Google Patents

conjugado de proteína, processo para preparação do dito conjugado de proteína, composição farmacêutica e processo para prolongar a meia vida útil in vivo de um polipeptídeo fisiologicamente ativo

Info

Publication number
BRPI0408331B8
BRPI0408331B8 BRPI0408331A BRPI0408331A BRPI0408331B8 BR PI0408331 B8 BRPI0408331 B8 BR PI0408331B8 BR PI0408331 A BRPI0408331 A BR PI0408331A BR PI0408331 A BRPI0408331 A BR PI0408331A BR PI0408331 B8 BRPI0408331 B8 BR PI0408331B8
Authority
BR
Brazil
Prior art keywords
protein conjugate
physiologically active
vivo half
active polypeptide
preparing
Prior art date
Application number
BRPI0408331A
Other languages
English (en)
Inventor
Lim Chang-Ki
Kim Dae-Jin
Lee Gwan-Sun
Kwon Se-Chang
Bae Sung-Min
Kim Young-Min
Original Assignee
Hanmi Holdings Co Ltd
Hanmi Science Co Ltd
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co Ltd, Hanmi Science Co Ltd, Hanmi Pharm Ind Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of BRPI0408331A publication Critical patent/BRPI0408331A/pt
Publication of BRPI0408331A8 publication Critical patent/BRPI0408331A8/pt
Publication of BRPI0408331B1 publication Critical patent/BRPI0408331B1/pt
Publication of BRPI0408331B8 publication Critical patent/BRPI0408331B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

conjugado de polipeptídeo fisiologicamente ativo possuindo meia vida útil in vivo prolongada. conjugado de proteína possuindo uma meia vida útil in vivo prolongada de uma atividade fisiológica, compreendendo i) um polipeptídeo fisiologicamente ativo, ii) um polímero não peptídico e iii) uma imunoglobulina, sendo útil para o desenvolvimento de um medicamento de polipeptídeo devido à estabilidade in vivo melhorada e meia vida útil prolongada no sangue, enquanto reduz a possibilidade de induzir uma resposta imune.
BRPI0408331A 2003-03-13 2004-03-13 conjugado de proteína, processo para preparação do dito conjugado de proteína, composição farmacêutica e processo para prolongar a meia vida útil in vivo de um polipeptídeo fisiologicamente ativo BRPI0408331B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2003-0015744 2003-03-13
KR20030015744 2003-03-13
KR20030036408 2003-06-05
KR10-2003-0036408 2003-06-05
PCT/KR2004/000535 WO2004081053A1 (en) 2003-03-13 2004-03-13 Physiologically active polypeptide conjugate having prolonged in vivo half-life

Publications (4)

Publication Number Publication Date
BRPI0408331A BRPI0408331A (pt) 2006-03-21
BRPI0408331A8 BRPI0408331A8 (pt) 2016-06-07
BRPI0408331B1 BRPI0408331B1 (pt) 2019-09-17
BRPI0408331B8 true BRPI0408331B8 (pt) 2021-05-25

Family

ID=36096009

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408331A BRPI0408331B8 (pt) 2003-03-13 2004-03-13 conjugado de proteína, processo para preparação do dito conjugado de proteína, composição farmacêutica e processo para prolongar a meia vida útil in vivo de um polipeptídeo fisiologicamente ativo

Country Status (16)

Country Link
US (2) US20050176108A1 (pt)
EP (1) EP1601698B1 (pt)
JP (1) JP4481980B2 (pt)
KR (1) KR100567902B1 (pt)
CN (2) CN1761684A (pt)
AT (1) ATE425188T1 (pt)
AU (1) AU2004220163B2 (pt)
BR (1) BRPI0408331B8 (pt)
CA (1) CA2519059C (pt)
DE (1) DE602004019887D1 (pt)
ES (1) ES2324298T3 (pt)
HK (1) HK1177465A1 (pt)
IL (1) IL170685A (pt)
PT (1) PT1601698E (pt)
RU (1) RU2312868C2 (pt)
WO (1) WO2004081053A1 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
ATE522548T1 (de) * 2003-11-13 2011-09-15 Hanmi Holdings Co Ltd Verfahren zur massenproduktion der konstanten region von immunglobulin
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
EP3153181A1 (en) 2004-11-12 2017-04-12 Bayer HealthCare LLC Site-directed modification of fviii bdd
EP1835938B1 (en) 2004-12-27 2013-08-07 Baxter International Inc. Polymer-von willebrand factor-conjugates
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
CA2609702C (en) * 2005-04-28 2013-05-28 Ventana Medical Systems, Inc. Antibody conjugates via heterobifunctional peg linkers
US20060269516A1 (en) * 2005-05-26 2006-11-30 Schering Corporation Interferon-IgG fusion
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007049940A1 (en) * 2005-10-27 2007-05-03 Peptron Co., Ltd Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
ES2677555T3 (es) 2005-11-23 2018-08-03 Ventana Medical Systems, Inc. Conjugado molecular
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
JP5800458B2 (ja) 2006-06-14 2015-10-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
WO2008154226A1 (en) * 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
WO2009024977A2 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US20090181037A1 (en) * 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
JP5546107B2 (ja) * 2008-04-17 2014-07-09 国立大学法人宇都宮大学 ＲＮＡウイルスＢｍＭＬＶ陰性カイコ培養細胞株
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
JPWO2010074082A1 (ja) * 2008-12-24 2012-06-21 塩野義製薬株式会社 バソヒビン修飾体
CN101585864B (zh) * 2009-01-05 2011-11-09 天津派格生物技术有限公司 柱层析粒细胞集落刺激因子氮端定点偶联方法及其产物
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
BRPI1013626B8 (pt) * 2009-03-20 2021-05-25 Hanmi Holdings Co Ltd método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico
US20120263701A1 (en) * 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
RU2519031C1 (ru) 2010-01-19 2014-06-10 Ханми Сайенс Ко., Лтд. Жидкие препаративные формы для длительно действующего конъюгата g-csf
KR101335765B1 (ko) * 2010-01-19 2013-12-02 한미사이언스 주식회사 지속형 에리스로포이에틴 결합체의 액상 제제
WO2011107992A2 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Multimeric forms of therapeutic proteins and uses thereof
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
RU2013127786A (ru) * 2010-11-19 2014-12-27 Венус Ремедиз Лимитед Новые конъюгаты для направленной доставки лекарственного средства
KR101309566B1 (ko) * 2010-12-10 2013-09-17 포항공과대학교 산학협력단 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
US9732333B2 (en) 2011-01-20 2017-08-15 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
CN102309765B (zh) * 2011-02-28 2013-10-16 北京韩美药品有限公司 包含免疫球蛋白Fc片段作为载体的长效抗凝多肽及其制备方法
RU2502803C2 (ru) * 2011-05-20 2013-12-27 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ПЛАЗМИДА ДЛЯ ЭКСПРЕССИИ В КЛЕТКАХ БАКТЕРИИ, ПРИНАДЛЕЖАЩЕЙ К РОДУ Escherichia, НЕАКТИВНОГО ПРЕДШЕСТВЕННИКА ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНОВ, БАКТЕРИЯ, ПРИНАДЛЕЖАЩАЯ К РОДУ Escherichia, - ПРОДУЦЕНТ НЕАКТИВНОГО ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНА, ПРЕДШЕСТВЕННИК РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНА, СПОСОБ ПОЛУЧЕНИЯ КОНЪЮГАТОВ ПОЛИЭТИЛЕНГЛИКОЛЯ И РЕКОМБИНАНТНОГО МУТЕИНА ДНКазы I ЧЕЛОВЕКА, ФЕРМЕНТАТИВНО АКТИВНЫЙ КОНЪЮГАТ МУТЕИНА РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102807619B (zh) * 2011-06-03 2016-08-03 北京韩美药品有限公司 含有免疫球蛋白Fc片段和粒细胞-巨噬细胞集落刺激因子的复合物及其药物组合物
CN102313773B (zh) * 2011-07-29 2013-11-20 首都师范大学 一种鉴定蛋白质中半胱氨酸数量的方法及其应用
RU2622077C2 (ru) 2011-09-05 2017-06-09 Ханми Сайенс Ко., Лтд. Фармацевтическая композиция для лечения рака, содержащая конъюгат интерферона-альфа
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN103172745A (zh) * 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
PL3564260T3 (pl) 2012-02-15 2023-03-06 Bioverativ Therapeutics Inc. Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania
AU2013204636B2 (en) 2012-02-15 2016-04-14 Bioverativ Therapeutics Inc. Recombinant Factor VIII proteins
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CN103235136B (zh) * 2012-04-28 2014-12-10 淄博高新区云桥生物技术研究所 蛋白质类药物三维构像的抗体阵序列检测方法
US9902753B2 (en) * 2012-06-05 2018-02-27 Cj Healthcare Corporation Method of purifying a long-acting human growth hormone
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR093387A1 (es) 2012-11-06 2015-06-03 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de proteina que comprende oxintomodulina y un fragmento de inmunoglobulina
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
CN103257237B (zh) * 2013-05-09 2015-05-20 中国农业大学 一种食品中过敏原的体外检测方法
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
KR102302634B1 (ko) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
WO2015046974A1 (ko) 2013-09-27 2015-04-02 한미약품 주식회사 지속형 인간 성장 호르몬 제제
JP6572497B2 (ja) 2013-12-18 2019-09-11 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
MA39301A1 (fr) * 2014-01-20 2018-01-31 Hanmi Pharmaceutical Co Ltd Insuline à action prolongée et utilisation associée
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US20180243364A1 (en) * 2015-03-17 2018-08-30 Omniox, Inc. Modulation of tumor immunity by protein-mediated 02 delivery
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
RU2656140C2 (ru) * 2016-11-14 2018-05-31 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Способ получения гибридного белка, состоящего из рекомбинантного белка аналога интерферона гамма, конъюгированного с олигосахаридом
CN111406073A (zh) * 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物
CN108164700B (zh) * 2017-12-27 2020-05-08 暨南大学 一种用于输送疏水性药物的活性氧响应性纳米载体及其制备方法
GB201801902D0 (en) * 2018-02-06 2018-03-21 Stichting Katholieke Univ Immunomodulatory nanofilaments
KR101974305B1 (ko) * 2018-02-14 2019-04-30 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US20240132566A1 (en) * 2019-10-16 2024-04-25 Jcr Pharmaceuticals Co., Ltd. Method for producing fusion protein of serum albumin and growth hormone
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2021261712A1 (en) * 2020-06-26 2021-12-30 Sunbio, Inc. Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE427505B (sv) * 1977-03-04 1983-04-11 Pharmacia Diagnostics Ab Reagens till anvendning vid immunkemiska bestemningsmetoder
US4487325A (en) * 1982-07-06 1984-12-11 Owens-Illinois, Inc. Crown closures and containers
GB8504099D0 (en) * 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
EP0513332A4 (en) * 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
CA2288429C (en) * 1991-03-15 2006-04-25 Synergen, Inc. Pegylation of polypeptides
DE69131426T2 (de) * 1991-04-17 2000-01-27 Medisup Int Nv Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone
CA2120023A1 (en) * 1992-07-28 1994-02-03 Noriaki Uenishi Immunoconjugate
CA2238307A1 (en) * 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life
CN1361793A (zh) * 1999-05-19 2002-07-31 利思进药品公司 干扰素－α蛋白作为Fc融合蛋白的表达和运输
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
EP1200124B1 (en) 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
AU7741000A (en) * 1999-09-30 2001-04-30 Icos Corporation Chitinase immunoglobulin fusion products
US20030211078A1 (en) * 2001-12-07 2003-11-13 Heavner George A. Pseudo-antibody constructs
JP2005539067A (ja) * 2002-09-16 2005-12-22 エリューシス セラピューティクス，インコーポレーテッド ポリエチレングリコールリンカーを用いる二重特異性分子の産生
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives

Also Published As

Publication number Publication date
CA2519059C (en) 2012-12-18
KR100567902B1 (ko) 2006-04-04
KR20040081378A (ko) 2004-09-21
JP4481980B2 (ja) 2010-06-16
DE602004019887D1 (de) 2009-04-23
CA2519059A1 (en) 2004-09-23
HK1177465A1 (zh) 2013-08-23
CN102757505B (zh) 2015-10-07
BRPI0408331A (pt) 2006-03-21
JP2007528346A (ja) 2007-10-11
US20050176108A1 (en) 2005-08-11
RU2312868C2 (ru) 2007-12-20
CN1761684A (zh) 2006-04-19
BRPI0408331B1 (pt) 2019-09-17
RU2005128504A (ru) 2006-03-10
WO2004081053A1 (en) 2004-09-23
ATE425188T1 (de) 2009-03-15
BRPI0408331A8 (pt) 2016-06-07
EP1601698A1 (en) 2005-12-07
AU2004220163A1 (en) 2004-09-23
PT1601698E (pt) 2009-06-17
EP1601698B1 (en) 2009-03-11
IL170685A (en) 2012-05-31
EP1601698A4 (en) 2006-05-03
CN102757505A (zh) 2012-10-31
IL170685A0 (en) 2009-02-11
US20100105869A1 (en) 2010-04-29
ES2324298T3 (es) 2009-08-04
AU2004220163B2 (en) 2008-01-31
US8163889B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
BRPI0408331B8 (pt) conjugado de proteína, processo para preparação do dito conjugado de proteína, composição farmacêutica e processo para prolongar a meia vida útil in vivo de um polipeptídeo fisiologicamente ativo
Skinner-Adams et al. Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
CY1105648T1 (el) Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης
CY1114945T1 (el) Φορεας φαρμακου και κιτ φορεα φαρμακου για την αναστολη ινωσης
MXPA05007210A (es) Complejo de proteina que usa un fragmento de inmunoglobulina y metodo para la preparacion del mismo.
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
BRPI0416796A (pt) compostos orgánicos
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
CY1107176T1 (el) Συνθεσεις και μεθοδος για θεραπεια μολυνσης σε βοοειδη και χοιρους
BRPI0519193A2 (pt) mÉtodo para produzir suspensÕes estÉreis ou liofilisados de complexos peptÍdicos bÁsicos fracamente soléveis, formulaÇÕes farmacÊuticas contendo os mesmos, e aplicaÇço dos mesmos como medicamentos
AR046877A1 (es) Muteinas del factor de crecimiento de fibroblastos 21
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
EA200602137A1 (ru) Гидрогелевые препараты интерферона
AR066199A1 (es) Metodo para reducir la concentracion del peptido amiloide beta
DK1056452T3 (da) Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter
CY1105008T1 (el) Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
RU2001132140A (ru) Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин VI и его применение в фармацевтике
CY1109001T1 (el) Οι καππα-οπιοιδεις αγωνιστες στη θεραπεια των παθησεων της κυστης
CY1106235T1 (el) Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων
CY1105116T1 (el) Χρηση των il-6r/il-6 χιμαιρων στη νοσο του huntington
DE60309480D1 (de) Vitamin d-analoge
DK1636261T3 (da) Thrombopoietinproteiner med forbedrede egenskaber

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: TRANSFERIDO DE: HANMI PHARM. CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF